ATE309382T1 - Rekombinante adenovirenvektoren zur gentherapie der menschlichen krebse - Google Patents

Rekombinante adenovirenvektoren zur gentherapie der menschlichen krebse

Info

Publication number
ATE309382T1
ATE309382T1 AT97914375T AT97914375T ATE309382T1 AT E309382 T1 ATE309382 T1 AT E309382T1 AT 97914375 T AT97914375 T AT 97914375T AT 97914375 T AT97914375 T AT 97914375T AT E309382 T1 ATE309382 T1 AT E309382T1
Authority
AT
Austria
Prior art keywords
gene therapy
recombinant adenovirus
human cancers
adenovirus vectors
disclosed
Prior art date
Application number
AT97914375T
Other languages
English (en)
Inventor
Falleur Boon
Marie-Therese Duffour
Hedi Haddada
Christophe Lurquin
Michel Perricaudet
Catherine Uyttenhoveghesquiere
Guy Warnier
Original Assignee
Aventis Pharma Sa
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa, Ludwig Inst Cancer Res filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of ATE309382T1 publication Critical patent/ATE309382T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT97914375T 1996-03-14 1997-03-12 Rekombinante adenovirenvektoren zur gentherapie der menschlichen krebse ATE309382T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9603207A FR2746110B1 (fr) 1996-03-14 1996-03-14 Methode de traitement par therapie genique des tumeurs humaines et virus recombinants correspondants
PCT/FR1997/000435 WO1997034009A1 (fr) 1996-03-14 1997-03-12 Vecteurs adenoviraux recombinants pour la therapie genique des tumeurs humaines

Publications (1)

Publication Number Publication Date
ATE309382T1 true ATE309382T1 (de) 2005-11-15

Family

ID=9490181

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97914375T ATE309382T1 (de) 1996-03-14 1997-03-12 Rekombinante adenovirenvektoren zur gentherapie der menschlichen krebse

Country Status (19)

Country Link
US (1) US20030082150A1 (de)
EP (1) EP0889969B1 (de)
JP (1) JP2000507229A (de)
KR (1) KR19990087718A (de)
CN (1) CN1218512A (de)
AT (1) ATE309382T1 (de)
AU (1) AU732288B2 (de)
BR (1) BR9707994A (de)
CA (1) CA2248612A1 (de)
CZ (1) CZ295967B6 (de)
DE (1) DE69734574T2 (de)
DK (1) DK0889969T3 (de)
ES (1) ES2252779T3 (de)
FR (1) FR2746110B1 (de)
HU (1) HUP9902150A3 (de)
IL (1) IL126152A0 (de)
NO (1) NO984052D0 (de)
SK (1) SK124698A3 (de)
WO (1) WO1997034009A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998015638A2 (en) * 1996-10-07 1998-04-16 Ludwig Institute For Cancer Research Replication-defective adenoviruses for cancer immunotherapy
CA2721011A1 (en) 1999-10-22 2001-05-03 Aventis Pasteur Limited Modified gp100 and uses thereof
US7851212B2 (en) * 2000-05-10 2010-12-14 Sanofi Pasteur Limited Immunogenic polypeptides encoded by MAGE minigenes and uses thereof
DE60238044D1 (de) * 2001-03-27 2010-12-02 Univ New York Tumortherapie mit vektoren auf sindbis virus-basis
US7786278B2 (en) 2002-04-09 2010-08-31 Sanofi Pasteur Limited Modified CEA nucleic acid and expression vectors
US20060073123A1 (en) * 2002-04-30 2006-04-06 Jie Mi Adenovirus vectors for immunotherapy
CN1327000C (zh) * 2002-09-06 2007-07-18 中国人民解放军军事医学科学院基础医学研究所 靶向黑色素瘤的可复制性腺病毒穿梭载体及腺病毒
WO2004037284A1 (en) * 2002-10-22 2004-05-06 Sanofi Pasteur Limited Anti-cancer vaccines and high-dose cytokines as adjuvants
US8562970B2 (en) * 2003-10-08 2013-10-22 Sanofi Pasteur Limited Modified CEA/B7 vector
CA3115891A1 (en) 2013-03-14 2014-09-25 Salk Institute For Biological Studies Oncolytic adenovirus compositions
DK3198009T3 (da) 2014-09-24 2021-11-22 Salk Inst For Biological Studi Onkolytiske tumorvira og anvendelsesfremgangsmåder
EP3390645B1 (de) 2016-02-23 2022-09-14 Salk Institute for Biological Studies Exogene genexpression eines therapeutischen adenovirus mit geringem einfluss auf die virale kinetik
JP7054527B2 (ja) 2016-02-23 2022-04-14 ソーク インスティテュート フォー バイオロジカル スタディーズ アデノウイルスの複製動態を測定するための高スループットアッセイ
CN110062630A (zh) 2016-12-12 2019-07-26 萨克生物研究学院 肿瘤靶向合成腺病毒及其用途
CA3096099A1 (en) 2018-04-09 2019-10-17 Salk Institute For Biological Studies Oncolytic adenovirus compositions with enhanced replication properties

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
US6235525B1 (en) * 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
US5620886A (en) * 1993-03-18 1997-04-15 Ludwig Institute For Cancer Research Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
NZ269156A (en) * 1993-07-13 1996-03-26 Rhone Poulenc Rorer Sa Defective recombinant adenovirus vector incapable of replicating autonomously in a target cell and its use in gene therapy

Also Published As

Publication number Publication date
KR19990087718A (ko) 1999-12-27
IL126152A0 (en) 1999-05-09
AU2164197A (en) 1997-10-01
HUP9902150A2 (hu) 1999-11-29
DK0889969T3 (da) 2006-03-27
WO1997034009A1 (fr) 1997-09-18
CN1218512A (zh) 1999-06-02
ES2252779T3 (es) 2006-05-16
JP2000507229A (ja) 2000-06-13
EP0889969A1 (de) 1999-01-13
DE69734574D1 (de) 2005-12-15
CZ295967B6 (cs) 2005-12-14
FR2746110B1 (fr) 1998-04-17
NO984052L (no) 1998-09-03
BR9707994A (pt) 1999-07-27
CA2248612A1 (fr) 1997-09-18
EP0889969B1 (de) 2005-11-09
NO984052D0 (no) 1998-09-03
SK124698A3 (en) 1999-05-07
US20030082150A1 (en) 2003-05-01
HUP9902150A3 (en) 2000-12-28
AU732288B2 (en) 2001-04-12
DE69734574T2 (de) 2006-07-13
CZ291598A3 (cs) 1998-12-16
FR2746110A1 (fr) 1997-09-19

Similar Documents

Publication Publication Date Title
ATE309382T1 (de) Rekombinante adenovirenvektoren zur gentherapie der menschlichen krebse
TW581808B (en) Compounds for immunotherapy of prostate cancer and methods for their use
BR0008161A (pt) Uso de uma composição terapêutica para tratamento de uma célula tumoral, composição terapêutica, e kit para tratamento de uma célula tumoral
DE69630890D1 (de) Peptid-immitierende substanzen in der krebstherapie
HUP0002095A2 (hu) Vegyületek prosztatarák immunterápiás kezelésére és alkalmazásuk
UA66417C2 (en) Recombinant adenovirus affecting canines, pharmaceutical composition
CY1105963T1 (el) Συνθεσεις καψομepιδιακου εμβολιου του ιου του θηλωματος και μεθοδοι χρησης
MY119276A (en) Pharmaceutical composition for immunomodulation based on peptides and adjuvants
NZ516381A (en) Lung tumor proteins in the therapy and diagnosis of lung cancer
FI951138A7 (fi) Puuttellisia adenovirusvektoreita ja niiden käyttö geeniterapiassa
AU2003242305A1 (en) Hla-a24-restricted cancer antigen peptide
HUP0203035A2 (hu) Prosztatarák terápiájára és diagnózisára alkalmas vegyületek és eljárások
MXPA03001389A (es) Composiciones y metodos para la terapia y diagnostico de malignidades asociadas con her-2/neu.
WO1999033869A3 (en) Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
NO20004631L (no) Forbindelser og fremgangsmÕter for terapi og diagnose av lungekreft
IT1298487B1 (it) Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale,
AR031250A1 (es) Composiciones y metodos para la terapia y el diagnostico del cancer de pulmon
BR9808509A (pt) Composições e métodos para o tratamento e diagnóstico do câncer de mama
YU65103A (sh) Peg-konjugati hgf-nk4
TR199901190T2 (xx) Interferon-(alfa) N�kleik asitlerinin verilmesi ve sentezlenmesi i�in y�ntemler ve bile�imler.
AR019844A1 (es) Polipeptidos composicion farmaceutica, procedimiento para preparar dicha composicion metodo para tratar y prevenir el cancer y metodo para inhibir elcrecimiento de celulas tumorales
ATE514780T1 (de) Zusammensetzungen für die therapie und diagnose von brustkrebs und verwendung davon
DK1007717T3 (da) Metoder og sammensætninger til cancerterapi under anvendelse af gener, der koder for interferon-beta
NO991653L (no) Immunogenisk tumor frigjorte partikler (TLP)-blanding
ATE193451T1 (de) Verotoxin pharmazeutische zusammensetzungen und damit medizinische behandlungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0889969

Country of ref document: EP

REN Ceased due to non-payment of the annual fee